Form 4: Foghorn Therapeutics Director Reports Stock Option Grant

Neil Gallagher, a Director at Foghorn Therapeutics Inc., reported the acquisition of 28,000 stock options with an exercise price of $4.08.

Summary

• Neil Gallagher, a Director of Foghorn Therapeutics Inc. (FHTX), has reported the acquisition of stock options.
• The transaction, dated June 24, 2026, involves 28,000 stock options with an exercise price of $4.08 per share.
• These options are exercisable on June 23, 2036, and vest in full on the first anniversary of the grant date, contingent upon continued service as a director.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it reports a standard stock option grant to a director, which is typical for executive compensation and does not inherently signal positive or negative company performance.

Positives

• Director Neil Gallagher has been granted a significant number of stock options (28,000), indicating potential future value tied to the company's performance.
• The vesting schedule, tied to continued service, aligns the director's incentives with the long-term success of Foghorn Therapeutics.

Risks

• The value of the stock options is contingent on the future performance of Foghorn Therapeutics' stock price, which could decline.
• Continued service as a director is required for the options to vest, implying a risk if the reporting person's tenure is interrupted.

Future Outlook

The filing itself does not contain forward-looking statements or guidance regarding the company's financial performance. It solely reports a transaction related to executive compensation.

Industry Context

StockSavvy.ai notes that the issuance of stock options to directors is a common practice in the biotechnology and pharmaceutical sectors, aligning executive incentives with shareholder value creation. This type of equity award is standard for retaining key leadership in companies focused on long-term research and development.

Stakeholder Impact

• Shareholders: The grant of options to a director aligns their interests with shareholders, potentially leading to decisions that enhance shareholder value. However, it also represents potential future dilution if options are exercised.

Key Dates

Keywords

Foghorn Therapeutics, FHTX, Form 4, Stock Options, Director, Beneficial Ownership, SEC Filing, Equity Award